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Abstract
Background: In pulmonary Mycobacterium tuberculosis (Mtb) infection, immune responses are delayed compared to other
respiratory infections, so that antigen-specific cells are not detected in the lungs earlier than day 14. Even after parenteral
immunization with Bacille Calmette Guerin (BCG) or a subunit vaccine, the immune response after Mtb challenge is only
slightly accelerated and the kinetics of pulmonary Mtb growth do not differ between naı ¨ve and immunized animals up to
day 14.
Methods and Findings: Mice were immunized intranasally with a recombinant adenovirus expressing mycobacterial
antigen 85A (Ad85A), challenged by aerosol with Mtb and the kinetics of Mtb growth in the lungs measured. Intranasal
immunization with Ad85A inhibits Mtb growth in the early phase of infection, up to day 8. Protection is sustained for at least
7 months and correlates with the presence of antigen-specific activated effector CD8 T cells in the lungs. Antigen 85A-
specific T cells respond to antigen presenting cells from the lungs of mice immunized with Ad85A 23 weeks previously,
demonstrating the persistence of antigen in the lungs.
Conclusions/Significance: Intranasal immunization with Ad85A can inhibit early growth of Mtb because it establishes a lung
antigen depot and maintains an activated lung-resident lymphocyte population. We propose that an optimal immunization
strategy for tuberculosis should aim to induce both lung and systemic immunity, targeting the early and late phases of Mtb
growth.
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Introduction
Tuberculosis causes 1.7 million deaths per year worldwide and
the emergence of HIV-associated mycobacterial infections, as well
as an increasing frequency of multi-drug resistant and extensively
drug resistant M. tuberculosis (Mtb) isolates, reinforces the need to
develop new control strategies. Immunization with Bacille
Calmette Guerin (BCG) confers a variable degree of protection
against disseminated disease in the very young but poor protection
against pulmonary disease in older age groups. However, because
of its partial efficacy, an attractive strategy is to develop vaccines
that can be used as boosters following BCG primary immuniza-
tion. Because CD4 T cell immunity and IFNc have been shown to
be important for immune control of Mtb many of the new vaccine
candidates aim to induce a Th1 type CD4 response. While some
have been shown to induce protective immunity equivalent to
BCG when given alone [1–4], these candidates seldom increase
convincingly protection over BCG, when they are used as booster
vaccines [5–8].
In contrast, recombinant adenoviruses expressing Mtb mycolyl
transferase antigen85A (Ad85A) have shown good protective effects
inseveralspecieswhengivenintranasally(i.n.)andalsoreproducibly
increase protection over BCG alone when given as a booster by this
route [9–11]. Ad85A induces strong CD8 immune responses
[10,12,13] and in mice, protection induced by i.n. immunization
has been shown to be associated with the presence of a large
population of antigen-specific CD8 T cells in the lungs [14]. This is
in line with more recent evidence that CD8 cells make an important
contribution to immune protection against Mtb [15–17].
A unique feature of pulmonary Mtb infection is that the innate
and adaptive immune responses occur much later than in other
respiratory infections. In mice, no T cell activation occurs in the
mediastinal nodes before 9–10 days post-aerosol Mtb infection and
antigen specific cells are not detected in the lungs earlier than day
14 [15,18,19]. Even in mice immunized with BCG, Mtb itself or a
subunit vaccine, cellular responses are only slightly accelerated.
This delay in cellular immune responses is in accord with the
kinetics of mycobacterial growth. Thus, over the first 15 days post-
infection mycobacterial growth does not differ between naı ¨ve and
immune mice [20–23]. However, the presence of large numbers of
CD8 T cells in the lungs of Ad85A i.n. immunized mice suggested
that this regime might induce protection by a different mechanism.
PLoS ONE | www.plosone.org 1 December 2009 | Volume 4 | Issue 12 | e8235Here we show that this is the case and mice immunized i.n. with
Ad85A suppress mycobacterial growth in the lungs during the first
week after Mtb aerosol challenge, in contrast to the delayed
inhibitory effect of parenteral immunization. As protection against
early growth of Mtb in the lungs has not been described previously,
we further investigated the nature of the cells present in the lungs
at the time of challenge and the duration of this form of protection
following immunization.
Results
Ad85A Immunization Targets the Early Phase of Mtb
Infection
Parenteral immunization with BCG generates mainly systemic
CD4-mediated protective immunity and few antigen-specific cells
are found in the airway lumen of the lungs [18,19,24,25].
However, because primary immunization or boosting with Ad85A
i.n. induces a large lung-resident CD8 population [10,12–14], we
investigated whether this method of immunization affects growth
of Mtb early after challenge.
Mice were immunized with BCG alone or primed with BCG
and boosted with Ad85A i.n. 10 weeks later. Four weeks after the
last immunization they were challenged with Mtb by the aerosol
route and mycobacterial load was quantitated at early time points.
Strikingly, in mice boosted with Ad85A the mycobacterial load in
the lungs does not increase up to 8 days after challenge, while
naı ¨ve and BCG-immunized animals show a steady increase in Mtb
CFU from day 3 onward and no difference in lung mycobacterial
load until day 21 post-challenge (Fig. 1A). Thus mice boosted with
Ad85A i.n. control Mtb by a different mechanism from BCG-only
mice. However, in order to exclude the effect of priming by BCG,
we also tested Mtb growth in animals immunized with Ad85A i.n.
only. We observed similar early inhibition of Mtb CFU, confirming
that immunization with Ad85A i.n. inhibits early Mtb growth, in
contrast to BCG, the effect of which only becomes apparent 21
days after Mtb infection (Fig. 1B).
Because of the early suppression of Mtb growth in the Ad85A
immunized mice, we examined the ability of lung cells from mice
immunized with Ad85A i.n. to inhibit Mtb growth in macrophages
in vitro (Fig. 1C). Lung cells from animals immunized i.n. with
Ad85A inhibit growth of Mtb on average by 25.2+/25.2%
compared to lung cells from naive mice (3.1+/26.5%, p=0.007).
Protection After Intranasal Administration of Ad85A Is
Long Lasting
Protective efficacy of tuberculosis booster vaccines is most often
tested at 4 to 6 weeks after boosting, at or near the peak of the
immune response. However, for a vaccine to be useful it is
important that durable protective memory is established. We
therefore examined protection against Mtb aerosol challenge at 4
and 24 weeks post-i.n. immunization with Ad85A.
When mice are challenged by aerosol 4 weeks after immuni-
zation with Ad85A i.n., Mtb lung CFU are reduced by ,1 log
compared to naı ¨ve animals, a similar reduction to that in mice
immunized with BCG. Ad85A i.n. on its own also reduces the Mtb
load in the spleen to a similar extent as BCG only (,2 logs)
(Fig. 2B). As previously described, the protective effects of BCG
priming followed by an Ad85A i.n. boost are approximately
additive in the lungs, although in this experiment no additive effect
was seen in the spleen [10,14].
BCG-induced protection is long-lasting in mice, so it was of
interest to examine whether this was the case for Ad85A i.n..
Figure 2C shows that the protective effect in lung and spleen
afforded by Ad85A on its own is sustained 24 weeks after i.n.
immunization (,1 log in lung and ,2 logs in spleen, p=0.03). A
second experiment with Mtb challenge at 30 weeks post-
immunization showed sustained reduction in CFU in BCG-
immunized (lung ,1 log reduction compared to naive p=0.004,
spleen ,1 log p=0.02) or Ad85A i.n.-immunized mice (lung ,0.6
log p=0.004, spleen ,0.6 log p=0.004). No reduction of CFU
was observed when Ad85A was administered i.d. either on its own
or as a booster following BCG (Table 1 and [14]).
Although we did not test the protective effect of BCG priming
and Ad85A i.n. boosting at 24 or 30 weeks, we did so at 14 weeks
and the protection afforded is still significantly better than BCG
alone (,0.5 log reduction in lung compared to BCG, p=0.016;
spleen ,1.4 log, p=0.009, data not shown) However, further
experiments to establish the durability of the additional protection
provided by intranasal boosting with Ad85A need to be performed.
Several different methods have been used for pulmonary
challenge with Mtb in mice and the challenge dose may also affect
the outcome of experiments [10,12,13]. We therefore tested
whether protection afforded by i.n. immunization with Ad85A is
seen after both low (,200 CFU, Fig. 2) or high dose (880 CFU)
Mtb aerosol challenge (Table 1) or when the mice are challenged
withMtbbythe intratrachealori.n.routes(Table 1). Irrespectiveof
the method, or dose of Mtb used for pulmonary Mtb challenge, i.n.
boosting with Ad85A significantly reduces lung and spleen CFU
compared to BCG alone, confirming earlier studies [6,9,10,12,13].
These results confirm previous findings that i.n. administration
of Ad85A induces robust protection when given on its own and
provides additional protection when given as a booster after BCG.
We also show that protection is sustained for at least 30 weeks.
Lung Antigen 85A Immune Responses
Because protection after i.n. administration of Ad85A correlates
with the presence of antigen-specific cells in the lung at 4 weeks [14],
we investigated whether these cells are present in the lung later after
immunization. We performed intracellular staining for IFNc, IL-2
and TNFa on lung cells stimulated with a pool of peptides covering
the whole protein sequence of antigen 85A (Fig. 3A).The peak of the
response is 4 weeks after immunization. At this time point mice
primed with BCG and boosted with Ad85A i.n. show a greater
response than mice immunized with Ad85A i.n. only, implying that
immunization with BCG primes for a subsequent booster response to
antigen85A.PreviouslyweobservednoprimingeffectofBCGonthe
85A response but here we used BCG SSI as opposed to Pasteur and a
different interval between priming and boosting, 8 weeks as opposed
to 10 weeks in our previous study [14]. In a separate repeat
experiment with a 10 week interval between the prime and boost, no
priming effect of BCG on the 85A response was observed, suggesting
that the priming effect is weak and inconsistent.
In BCG primed, Ad85A i.n. boosted animals at the peak of the
response, ,8% of the lung CD8 T cells produce IFNc in response
to the pool of 85A peptides. As previously shown many fewer CD8
cells produce IL-2, while TNFa production is similar to IFNc [14].
The CD8 response declines from 8% to ,1% of lung CD8 cells at
23 weeks. CD4 responses are relatively low and 0.4% and 0.1% of
the CD4 cells are antigen-specific at 4 and 23 weeks respectively
(Fig. 3B). A low response (0.5% of CD8 cells) is detected in the
spleen and peripheral blood following i.n. vaccination.
Because triple cytokine-producing cells have been suggested to
be important for protection against some chronic infections,
including Mtb [26], we analysed the proportions of single (1+),
double (2+) and triple (3+) cytokine-producing CD8 85A- specific
cells at 4 and 23 weeks (Fig. 3C and D). There are some 3+ cells
at 4 weeks, as there is some IL-2 production. However these
disappear rapidly and at week 23 there are mainly 2+ and 1+ cells.
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numbers of cytokines is detected between the prime and prime-
boost regimes. Nor was there any change over time of the median
fluorescence intensity of staining for intracellular IFNc, IL-2 and
TNFa in animals immunized with Ad85A i.n. only.
Parenteral i.d. immunization induces a long-lived splenic
immune response which lasts for at least 23 weeks. The magnitude
and duration of the antigen-specific CD8 response in the spleen of
i.d. Ad85A immunized animals is very similar to the lung response
in Ad85A i.n. immunized animals, with 3% of splenic antigen-
Figure 1. Early control of mycobacterial growth by intranasal administration of Ad85A. BALB/c mice were immunized with BCG or primed
with BCG and 10 weeks later boosted with Ad85A i.n. (A) or immunized only with Ad85A i.n. (B) Naı ¨ve mice were used as controls. Mice were
challenged with Mtb by aerosol 4 weeks after the last immunization and sacrificed at days 1, 3, 8, 14, 21 and 28. Lung and spleen CFU were
enumerated. Results are expressed as the mean counts of 5–7 mice per group. * p,0.05 Ad85A or B-Ad85A immunized mice versus Naı ¨ve or BCG,
**p,0.05 for B-Ad85A versus Naı ¨ve, BCG versus B-Ad85A, BCG versus Naı ¨ve. Similar results were obtained in a repeat experiment. Standard deviations
are small, so that the error bars are within the symbols when not visible. (C) Inhibition of Mtb growth in macrophages by lung cells in vitro. Murine
peritoneal macrophages were infected with Mtb and co-cultured with lung cells from naı ¨ve mice or mice immunized with Ad85A i.n. 3 weeks
previously. Inhibition of mycobacterial growth was determined after 3 days. Results are expressed as the mean % inhibition +/2 SEM of four
experiments with four mice per group.
doi:10.1371/journal.pone.0008235.g001
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both the prime and prime-boost regimes. Despite this, Ad85A i.d.
immunization does not reduce mycobacterial load on its own, nor
does it further reduce the load when administered as a boost,
confirming that the induction of a strong systemic immune response
does not correlate with protection in this mouse model [14].
Having shown that i.n. immunization with Ad85A establishes a
stable, long-lived protective immune response against infectious
challenge, we further characterised the antigen-specific T cells.
Antigen-specific IFNc
+CD8 cells were identified as effector
(CD62L
2CD127
2), effector memory (CD62L
2CD127
+)a n d
central memory cells (CD62L
+CD127
+) [27] (Fig. 4A). In the
lung, antigen-specific cells are predominantly effectors, 70% and
52% respectively at 4 and 23 weeks post-immunisation and the
remaining cells are effector memory phenotype (30% and 48%
respectively). In contrast, although there were very few antigen-
specific cells in extra-pulmonary sites of these i.n. immunised
animals, those in the spleen and blood are predominantly effector
memory phenotype at 4 and 23 weeks (Fig. 4A).
When mice are immunized i.d. with Ad85A, the splenic and blood
antigen-specific cells have the same phenotype as the much smaller
number of cells present in these organs after i.n. immunization
(Fig. 4A). Therefore irrespective of the route of immunization, blood
and splenic antigen-specific cells are less activated than those in the
lung, confirming previous observations that cells that home to non-
lymphoid tissues display an activated phenotype [28,29].
Because down-regulation of CD27 has been associated with
activation and persistent antigenic stimulation, we analysed CD27
Figure 2. Intranasal administration of Ad85A increases protection at 4 and 24 weeks. (A) Time line of the experiment. BALB/c mice were
immunized with BCG, or primed with BCG and 10 weeks later boosted intranasally with Ad85A (B-Ad85A i.n.), or immunized only with Ad85A i.n.
Naı ¨ve mice were used as challenge controls. Mice were challenged with Mtb by aerosol 4 (B) or 24 (C) weeks after the boost. Deposition in the lungs
was measured 24 h after challenge and was ,200 CFU/lung. Mice were sacrificed 6 weeks later and lung and spleen CFU enumerated. Symbols show
CFU counts of individual mice and the horizontal line indicates the mean. * p,0.05 versus Naı ¨ve, **p,0.05 versus BCG. Similar results were obtained
in two other experiments where the lungs and spleens were harvested at 4 weeks post Mtb challenge.
doi:10.1371/journal.pone.0008235.g002
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cells in the lung lack expression of CD27 compared to total CD8
cells, suggesting that the lung might contain antigen 85A, even at
23 weeks post-immunisation.
In summary, persistent antigen-specific responses are detected
in the lungs following i.n. administration of Ad85A. Long-term
memory in the lungs of i.n. immunised animals is biased towards
effector type CD8 T cells producing mainly IFNc and TNFa.
Presence of Antigen 85A in the Lungs
As we detect antigen-specific cells in the lungs at 23 weeks post-
immunisation and because they lack CD27 surface expression, we
next examined whether antigen is still present in the lungs. We
used lung cells isolated 23 weeks post-Ad85A i.n. immunisation as
APCs to stimulate T cells isolated from the spleens of animals
immunized i.d. with Ad85A (Fig. 4C). The responding T cells
were labelled with CFSE and co-cultured with unlabelled lung
APCs. As more than 90% of the CD8 antigen-specific cells
recognise the dominant H-2L
d antigen 85A peptide 70–78aa
(MPVGGQSSF), this tetramer was used to detect antigen-specific
cells responding to the lung APCs. After 5 days CFSE intensity of
tetramer positive cells was analysed and compared to the same
cells co-cultured with lung APCs from naı ¨ve animals. After co-
culture with APCs from Ad85A i.n. animals, tetramer binding cells
undergo several cell divisions, whereas cells co-cultured with lungs
cells from naı ¨ve animals do not, indicating that 85A antigen,
capable of inducing T cell proliferation, is present in the lungs 23
weeks post-immunization (Fig. 4C). Although we did not include
an empty adenovirus control, since only the tetramer positive
splenic T cells proliferated and not other activated CD8 cells in the
splenic T cell population, it appears that proliferation is antigen
specific, rather than a response to inflammatory cytokines.
Discussion
Pulmonary Mtb infection is unlike other respiratory infections
because innate and adaptive immune responses to Mtb are
delayed. T cell activation in the mediastinal nodes only occurs
9–10 days post-infection, while antigen-specific cells are not
detected in the lungs until day 14 [18,19]. Although not fully
understood, this delay may be due to low antigen dose (50–200
mycobacteria), naturally low inflammatory responses in the lung
or active inhibition of antigen presentation by Mtb [18]. Whatever
the reasons, a consequence is that mechanisms for promoting
entry of systemic antigen-specific cells, such as up-regulation of
VCAM-1, are not activated until two weeks post-infection [31]. It
is therefore understandable that parenteral immunization against
Mtb provides no protection against initial growth of mycobacteria
following pulmonary challenge [20–23]. Here we demonstrate for
the first time that a protective Ad85A vaccine administered i.n.
exerts its effect by suppression of mycobacterial growth during the
first week after Mtb infection, in contrast to the delayed inhibitory
effect of parenteral vaccines.
Ad85A and recombinant adenoviruses containing other anti-
gens of Mtb administered i.n. are highly protective in mice and
induce large populations of lung-resident CD8 T cells [4,9,12,14].
These remain largely confined to the lungs because of endothor-
acic recirculation [29]. Even six months after immunization with
Ad85A i.n, there is a significant population of antigen-specific cells
in the lungs and their presence correlates with protection against
Mtb. More than 50% of lung 85A-specific CD8 cells are of effector
phenotype, even at 23 weeks post-immunization and the majority
have down-regulated CD27, a phenotype that is thought to
indicate continual exposure to antigen and correlates with
expression of granzyme B and perforin [30]. The proliferation of
85A-specific T cells in response to lung cells of mice immunized six
months previously with Ad85A, provides direct evidence for
persistence of antigen, confirming other data showing persistence
of adenoviral sequences up to 2 years post-intramuscular
immunization [32].
Although cells from the lungs of mice immunized with Ad85A
i.n. reduced Mtb CFU of infected macrophages in vitro we do not
know the exact mechanism by which early inhibition of growth in
vivo is achieved. Indeed, there is little clarity regarding the cellular
and molecular mechanisms of the immune responses that limit Mtb
growth after infection of naı ¨ve animals, or mediate vaccine-
induced protection. BCG induces mainly CD4 T cells producing
TNFa and IFNc as well as multifunctional cells [24,26] and an
extensive literature indicates the importance of CD4 T cells in
immunity to Mtb [18]. We do not know whether lung cells from
BCG-immunized mice inhibit Mtb growth in macrophages but it
will be of interest to compare them with lung cells from Ad85A-
immunized mice in future experiments. However, it is clear that
CD8 T cells can also play a role in protection [15,17,18].
Administration of Ad85A i.n. induces a strong and durable antigen
85A-specific lung CD8 response of effector and effector memory
phenotype and these CD8 cells may function by producing IFNc
and by targeting infected cells for cytolysis, using several cytolytic
pathways [17]. It is also possible that immunization with Ad85A
i.n. recruits or activates other leucocytes such as neutrophils and
macrophages that could contribute to inhibition of early growth of
Mtb. Evidence that IL-17 is associated with protective immunity in
cattle and mice may suggest that this is the case [6,19,22]. Further
work will elucidate the exact mechanisms and genes involved in
early control of Mtb growth in the lungs.
Recombinant adenoviruses administered i.n. are a highly
effective means of inducing mucosal immunity, CD8 T cells and
protection against Mtb, but there is some controversy as to the
efficacy of parenteral immunization with similar recombinant
vectors. We have previously shown that i.d. boosting with Ad85A
does not significantly increase protection over that afforded by
Table 1. Comparison of protection after different methods of
pulmonary infection with Mtb.
Lung I.N. I.T. aerosol
Naive 6.45 60.33 6.58 60.41 6.36 60.22
B 5.53 60.39* 5.36 60.60 5.75 60.32*
BA i.d. 5.41 60.36* 5.07 60.23* 5.35 60.63*
BA i.n. 4.62 60.14** 3.20 60.57** 4.95 60.48**
Spleen I.N. I.T. aerosol
Naive 4.71 60.25 4.40 60.38* 5.62 60.19
B 4.25 60.34* 4.45 60.25* 3.95 60.16*
BA i.d. 4.15 60.43* 4.10 60.43* 3.22 60.83*
BA i.n. 3.21 60.36** 2.45 60.72** 3.38 60.62*
BALB/c mice were immunized with BCG, or primed with BCG and 8 weeks later
boosted with Ad85A given intradermally (BA i.d.) or intranasally (BA i.n.). Naı ¨ve
mice were used as controls. Mice were challenged with Mtb 4 weeks after the
last immunization intranasally (I.N.), intratracheally (I.T.) or by aerosol.
Deposition in the lungs was measured 24 h after challenge and was
,1000 CFU per lung after I.N., 620 CFU after I.T. and 880 CFU after aerosol Mtb
challenge. Mice were sacrificed 4 weeks later and lungs and spleen CFU
enumerated. Data represent the mean +/2 SD from 6–8 mice per group.
*p,0.05 versus naı ¨ve.
**p,0.05 versus BCG and BA i.d.
doi:10.1371/journal.pone.0008235.t001
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PLoS ONE | www.plosone.org 5 December 2009 | Volume 4 | Issue 12 | e8235Figure 3. Cytokine responses of lung T cells to antigen 85A. Mice were immunized with Ad85A i.n. (Ad85A i.n.) or primed with BCG and
boosted 8 weeks later with Ad85A intranasally (B-Ad85A i.n.). Lung cells were isolated at the indicated times after the last immunization and
stimulated with pooled 85A peptides for 6 hours. The frequencies of IFNc, IL-2 and TNFa producing cells were determined by flow cytometry on CD8
(A) and CD4 (B) gated cells. Pie charts indicate the proportions of single (light grey), dual (dark grey) and triple (black) CD8 producers of IFNc, TNFa
and IL-2 in the lungs of mice 4 (C) and 23 (D) weeks after immunization. Results are expressed as the mean +/2 SEM of three/four mice per group,
representative of two independent experiments.
doi:10.1371/journal.pone.0008235.g003
Distinct Phase Immunization
PLoS ONE | www.plosone.org 6 December 2009 | Volume 4 | Issue 12 | e8235BCG alone in mice challenged by aerosol [14], but because others
have used different methods we compared aerosol, intratracheal
and intranasal pulmonary challenge. In all cases, an i.d. Ad85A
boost after BCG priming did not significantly increase protection,
although there was a trend toward lower CFU in the boosted mice.
On the other hand, intramuscular (i.m.) boosting with Ad85A in
mice and guinea pigs clearly provides at least transient protection
[11]. In mice, it has been shown that Ad85A i.m. immunization
elicits transient lung immune responses [13] but the responding
cells are not localised in the airway lumen, in contrast to the
situation following i.n. immunization [12]. The transient nature of
pulmonary protection in these experiments is therefore most likely
because cells that enter the lungs after parenteral immunization do
not remain there in the absence of antigen. This explanation is
supported by experiments in which recombinant 85A protein was
introduced into the trachea of mice immunized parenterally with
recombinant Ad85A, leading to more sustained protection against
pulmonary challenge [12].
Several recent studies have demonstrated that it is possible to
generate protective immunity equivalent to that of BCG by
parenteral immunization. The most successful regimes employ
recombinant proteins given repeatedly in adjuvants [3,7]. However,
there is little evidence that such regimes provide consistently
increased protection over BCG when used as boosters. We suggest
that the principal reason why immunization with Ad85A i.n.
consistently provides additive protection when given as a booster
after BCG is that it generates a depot of antigen in the lungs that
both maintains an antigen-specific population and ensures that the
antigen–specific cells remain in an activated state, able to mediate
early protective immune responses to pulmonary Mtb challenge.
Nevertheless it remains possible that some parenteral immunization
methods may also induce cell populations that might provide
protection in the lungs early after pulmonary challenge. A recent
study in rhesus macaques provides some encouragement, as
repeated immunization with different recombinant adenoviruses
expressing SIV Gag resulted in potent, durable and functional CD8
responses at multiple mucosal surfaces [33,34].
In conclusion, our data confirm and extend previous results
showing that i.n. administration of Ad85A provides robust
protection against pulmonary tuberculosis in BALB/c mice. We
show that protection is sustained for at least 7 months and
correlates with the presence of an antigen-specific CD8 T cell
response in the lungs. Intranasal immunization with Ad85A
prevents an increase in Mtb CFU in the lungs during the first week
after pulmonary challenge. In contrast, following parenteral
immunization with BCG or an ESAT6 peptide subunit vaccine,
inhibition of mycobacterial growth is only seen later after Mtb
infection (.15 days) [22,23]. Therefore we propose that an
optimal immunisation strategy should target both phases of
mycobacterial infection. Intranasal immunization targets the early
phase because it establishes a lung antigen depot and an activated
lung-resident lymphocyte population. Parenteral immunization
with a protective antigen (BCG or ESAT6) establishes systemic
immunity, but systemic Mtb-specific cells only enter the lungs
when the challenge Mtb has caused sufficient inflammation to
recruit circulating leucocytes [20–23].
Current prime-boost strategies assume that BCG primes for Mtb
antigen(s) present in the booster vaccine and therefore generate a
more powerful protective response, but even the parenteral prime-
boost regimes currently entering clinical trials do not provide
statistically significantly better protection than BCG alone [5–7].
In contrast we suggest that parenteral Ad85A i.n. and BCG have
an additive effect because they target early and late phases of Mtb
growth, not because BCG primes for an 85A response. Formal
Figure 4. Phenotype of antigen-specific cells following intrana-
sal immunization with Ad85A. Mice were immunized as described in
the legend to Fig. 2 and lung cells stained for CD8, IFNc, CD62L and
CD127 (A) or CD27 (B). All results are from Ad85A i.n. mice at 4 and 23
weeks. Similar data were obtained from B-Ad85A i.n. mice. Results are
expressedas the mean+/2 SEMfrom three or four mice exceptfor blood
where the PBMCs from three/four mice were pooled. Similar results were
obtained from two independent experiments. (C) Persistence of antigen
85A in the lungs. Cells from the lungs of mice immunized 23 weeks
previously with Ad85A i.n. (open histogram) or naı ¨ve control mice
(shaded histogram) were used as APCs and co-cultured with CFSE-
labelled 85A-specific splenic T cells. Cells were recovered at day 5 and
stained with H-2L
d 85A peptide 70–78aa (MPVGGQSSF) tetramer. The
histogram shows the CFSE profile of 85A tetramer positive CD8 cells. The
result of one representative experiment of three is shown.
doi:10.1371/journal.pone.0008235.g004
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vaccines containing different antigens to generate separate lung
and systemic immune responses. Meanwhile we propose that
mucosal and parenteral immunization, targeting the early and late
phases of infection, most likely via different antigens, is a rational
strategy to improve protective immunity to Mtb.
Materials and Methods
Ethics Statement
All animal experiments were approved by the animal use ethical
committee of Oxford University and fully complied with UK
Home Office guidelines.
Construction of a Recombinant Adenovirus Expressing
Antigen 85A
The human tissue plasminogen activator leader sequence was
fused to the coding region of Mtb 85A (nt 99797 to nt 98910, lacking
the leader sequence) (Geneart), subcloned into pDONR221 vector,
then recombined into E1/E3 deleted AdHu5 (pAd/CMV/V5-
Dest) (Invitrogen) following the manufacturer’s instructions. A
replication-deficient AdHu5-85A recombinant virus clone was
amplified in E.coli, digested with PacI and transfected into 293A
cells to produce an adenoviral stock. Bulk virus was produced by
infecting 293A cells with the stock, then purified (PureSyn), and
quantitated by spectrophotometry. This construct demonstrated
similar immunogenicity and protection against aerosol Mtb
challenge as another recombinant Adenovirus-85A construct [14].
Animals and Immunizations
All experiments were performed on 6–8 week old female BALB/c
mice (Harlan Orlac). BCG (SSI) was administered subcutaneously in
the left hind footpad (2610
5 colony forming units (CFU)/30 ml). For
i.d. boosting, mice were anaesthetized and immunized with 25 mli n
each ear (2610
9 virus particles (vp) of Ad85A per mouse), and for i.n.
boosting allowed to slowly inhale 50 mlo f2 610
9 vp of Ad85A. Mice
were also immunized with Ad85A without prior BCG priming.
Pulmonary M. tuberculosis Challenge
Four to 30 weeks after Ad85A immunization, aerosol or
intratracheal challenge with Mtb (Erdman strain, CBER/FDA)
was performed as described [14,35]. For i.n. infection, anaesthe-
tized mice were allowed to inhale 50 mlo fMtb. Deposition in the
lungs was measured 24 h later. Mice were sacrificed at the
indicated times; the Mtb load in spleens and lungs was determined
by plating 10-fold serial dilutions of tissue homogenates on
Middlebrook 7H11 agar plates (E & O Laboratories Ltd).
Cell Isolation and Flow Cytometry
Lungs were perfused with PBS, minced and digested with 0.7 mg/
ml collagenase type 1 (Sigma) and 30 mg/ml DNase 1 (Sigma) for
45 mins at 37uC, then passed through a cell strainer, washed and
monuclear cells selected by density centrifugation on Lympholyte
(Cederlane). Spleens were passed through a cell strainer and
erythrocytes were lysed with RBC lysis solution (Qiagen). Peripheral
blood was collected in heparinized tubes from 3–4 mice per group,
diluted with DMEM and purified over Lymphoprep (Axis-Shield).
Isolated lymphocytes were cultured in DMEM+10% FCS, L-
glutamine, 2-mercaptoethanol, penicillin and streptomycin and
stimulated with either a pool of 66 15-mer peptides overlapping by
10 amino acids encompassing the entire 85A protein, or with the
dominant CD4 (Ag85A99–118aa TFLTSELPGWLQANRHVKPT)
and CD8 (Ag85A70–78aa MPVGGQSSF and Ag85A145–152aa YA-
GAMSGL) peptide epitopes [36,37] at 2 mg/ml (Peptide Protein
Research) for 6 hours at 37uC, with the addition of GolgiPlug (BD
Biosciences) 1 hour post-stimulation.
For intracellular cytokine staining, the Cytofix/Cytoperm kit
(BD Biosciences) protocol was employed. Cells were washed,
treated with Fc block (eBiosciences), then stained with combina-
tions of CD4 (clone RM4–5), CD27 (LG.7F9), CD127 (A7R34),
CD62L (MEL-14), IFNc (XMG1.2), IL-2 (JES6-5H4), TNFa
(MP6-XT22) (eBioscience) or CD8 (53-6.7) depending on the
experiment. The H-2L
d 85A peptide 70–78aa (MPVGGQSSF)
tetramer (NIH Tetramer Facility) for the dominant 85A epitope in
H-2
d mice was used in some experiments to enumerate antigen-
specific CD8 cells. Cells were fixed with PBS+1% paraformalde-
hyde, run on an LSRII (BD Biosciences) and analysed on Flow Jo
(Tree Star Inc). 3–4 individual mice were analysed per group.
Cytokine producing cell frequencies and numbers presented are
after background subtraction of an identically gated population of
cells from the same sample, incubated without peptide.
Detection of Antigen 85A in Lung Cells
Lung cells were prepared from mice immunized with Ad85A i.n.
23 weeks previously. CD8 T cells were removed using CD8
Microbeads and the remaining antigen presenting cells (APCs) were
plated in 48-well plates (8610
5 cells per well in 1 ml of RPMI+10%
FCS, L-glutamine). To generate CFSE-labeled responder cells,
CD4 and CD8 T cells were positively isolated (Miltenyi) from single
cell suspensions of splenocytes of mice immunized with Ad85A i.d.
20 weeks earlier, then labeled with CFSE (Invitrogen), washed and
added to the APCs at a concentration of 2610
5 cells per well. APCs
andresponder T cells were incubatedfor 5 daysat 37uC. Recovered
cells were labeled with H-2L
d 85A peptide 70–78aa (MPVGGQSSF)
tetramer, CD19 (1D3), CD8 and 7AAD to exclude dead cells.
Proliferation of the tetramer specific population of CFSE-labeled
CD8 T cells was measured on an LSRII.
Mycobacterial Growth Inhibition Assay
The assay was performed as described [14]. Peritoneal macro-
phages were plated at 15,000 cells per well in U-bottomed 96 well
microtiter plates and incubated at 37uC overnight. Non-adherent
cells were removed and adherent cells were infected with Mtb
overnight at a MOI of 5:1. Lung cells isolated from Ad85A i.n.-
immunized or naı ¨ve animals were added at an effector to target ratio
of 12:1. After 72 hours co-culture, 0.2% saponin was added for
1 hour to release Mtb. Viable organisms were quantitated by plating
on 7H11 agar. Results are expressed as % inhibition of mycobacterial
growth calculated by the formula, C-E/C x100, where C is the
number ofCFUin cultures of infected macrophagesin medium alone
and E is the number of CFU in co-cultures containing lung cells from
either naı ¨ve or Ad85A i.n.-immunized animals.
Statistical Analysis
All results are representative of at least two independent
experiments with similar results. Data were analysed using the
non-parametric Mann-Whitney test.
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